 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Treating Obesity in Type 2 DM: What's New?"Dr. Jeannette Goguen (biography)
English - 2006-04-28 - 30 minutes
|
 | (39 slides) |
Summary :
Diabetes and obesity are intimately linked, says Dr. Goguen. Not only does visceral obesity lead to insulin resistance and diabetes but some antidiabetic agents also cause weight gain. Would stopping weight gain or promoting weight loss reduce the risk of cardiovascular disease in these patients?
Of the several components of weight loss programs, Dr. Goguen focuses on pharmacological treatment with orlistat, sibutramine and rimonabant. It is important to recognize certain problems that exist with drug trials in obesity, including high drop-out rates, a lack of proof of reduction in cardiovascular disease and/or mortality, and reduced drug effectiveness without concomitant diet and exercise.
Dr. Goguen talks about the modes of action, contraindications, side effects and dosages of orlistat, sibutramine and rimonabant, as well as their effects on cardiovascular risk factors and body weight with a focus on studies in diabetic patients.
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
1. To know the benefits and risks for the use of each of the following medications to treat obesity in diabetes:
a. Sibutramine
b. Orlistat
c. Rimonabant
2. To understand limitations of drug studies in obesity
Bibliographic references :
J. Bruce Redmon, MD, Kristell P. Reck, RD, Susan K. Raatz, PHD, Joyce E. Swanson, RD, Christine A. Kwong, RD, Hong Ji, MS, William Thomas, PHD and John P. Bantle, MDTwo-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes Diabetes Care 28:1311-1315, 2005.
NEW DRUG TREATS MULTIPLE PROBLEMS OF PEOPLE WITH TYPE 2 DIABETES: Rimonabant Lowers Blood Glucose and Reduces Weight, Waist Size, and Lipid Problems American Diabetes Association.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
